TLR9 and neoplasm: In murine tumor models (CRC (CT26), melanoma (B16) and PDAC (Panc02)), Anz et al. recently demonstrated that CpG treatment (TLR9 ligand) specifically reduced the tumor infiltration by Tregs without affecting spleen Tregs or other TA-T cells, indicating a specific inhibition of Treg migration into the TME [357].